IRE1α silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer.

Autor: Xu L; Department of Experimental Therapeutics, James P. Allison Institute, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA., Peng F; Department of Molecular and Cellular Biology, Lester and Sue Smith Breast Center, Dun L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA., Luo Q; Department of Experimental Therapeutics, James P. Allison Institute, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA., Ding Y; Department of Experimental Therapeutics, James P. Allison Institute, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA., Yuan F; Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030, USA., Zheng L; Therapeutic Innovation Center (THINC), and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA., He W; Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Zhang SS; Department of Chemistry, Rice University, Houston, TX 77005, USA., Fu X; Department of Pathology, Xijing Hospital, Xi'an, Shaanxi 710032, China., Liu J; Department of Pathology, Xijing Hospital, Xi'an, Shaanxi 710032, China., Mutlu AS; Therapeutic Innovation Center (THINC), and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA., Wang S; Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Nehring RB; Therapeutic Innovation Center (THINC), and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA., Li X; College of Animal Science and Technology, Sichuan Agricultural University, Chengdu, Sichuan 611130, China., Tang Q; College of Animal Science and Technology, Sichuan Agricultural University, Chengdu, Sichuan 611130, China., Li C; Department of Experimental Therapeutics, James P. Allison Institute, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA., Lv X; Department of Experimental Therapeutics, James P. Allison Institute, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA., Dobrolecki LE; Department of Molecular and Cellular Biology, Lester and Sue Smith Breast Center, Dun L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA., Zhang W; Department of Molecular and Cellular Biology, Lester and Sue Smith Breast Center, Dun L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA., Han D; Department of Molecular and Cellular Biology, Lester and Sue Smith Breast Center, Dun L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA., Zhao N; Department of Molecular and Cellular Biology, Lester and Sue Smith Breast Center, Dun L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA., Jaehnig E; Department of Molecular and Cellular Biology, Lester and Sue Smith Breast Center, Dun L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA., Wang J; Department of Molecular and Cellular Biology, Lester and Sue Smith Breast Center, Dun L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA., Wu W; Department of Experimental Therapeutics, James P. Allison Institute, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA., Graham DA; Department of Molecular and Cellular Biology, Lester and Sue Smith Breast Center, Dun L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA., Li Y; Therapeutic Innovation Center (THINC), and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA., Chen R; Therapeutic Innovation Center (THINC), and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA., Peng W; Department of Biology and Biochemistry, University of Houston, Houston, TX 77204, USA., Chen Y; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Catic A; Department of Molecular and Cellular Biology, Lester and Sue Smith Breast Center, Dun L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA., Zhang Z; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Zhang B; Department of Molecular and Cellular Biology, Lester and Sue Smith Breast Center, Dun L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA., Mustoe AM; Therapeutic Innovation Center (THINC), and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA., Koong AC; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Miles G; Department of Molecular and Cellular Biology, Lester and Sue Smith Breast Center, Dun L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA., Lewis MT; Department of Molecular and Cellular Biology, Lester and Sue Smith Breast Center, Dun L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA., Wang MC; HHMI Janelia Research Campus, Ashburn, VA 20147, USA., Rosenberg SM; Therapeutic Innovation Center (THINC), and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA., O'Malley BW; Department of Molecular and Cellular Biology, Lester and Sue Smith Breast Center, Dun L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA., Westbrook TF; Therapeutic Innovation Center (THINC), and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA., Xu H; Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Zhang XH; Department of Molecular and Cellular Biology, Lester and Sue Smith Breast Center, Dun L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA., Osborne CK; Department of Molecular and Cellular Biology, Lester and Sue Smith Breast Center, Dun L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA., Li JB; Department of Genetics, Stanford University, Stanford, CA 94305, USA., Ellis MJ; Department of Molecular and Cellular Biology, Lester and Sue Smith Breast Center, Dun L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA., Rimawi MF; Department of Molecular and Cellular Biology, Lester and Sue Smith Breast Center, Dun L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA., Rosen JM; Department of Molecular and Cellular Biology, Lester and Sue Smith Breast Center, Dun L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA., Chen X; Department of Experimental Therapeutics, James P. Allison Institute, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA; Department of Molecular and Cellular Biology, Lester and Sue Smith Breast Center, Dun L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA. Electronic address: xchen23@mdanderson.org.

Publikováno v: Cell [Cell] 2024 Oct 14. Date of Electronic Publication: 2024 Oct 14.

PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer.

Autor: Chen A; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.; Integrative Molecular and Biomedical Sciences Program, Baylor College of Medicine, Houston, Texas.; Repare Therapeutics, Cambridge, Massachusetts., Kim BJ; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas., Mitra A; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas., Vollert CT; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.; Employee of Adrienne Helis Malvin Medical Research Foundation, New Orleans, Louisiana., Lei JT; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.; Department of Human and Molecular Genetics, Baylor College of Medicine, Houston, Texas., Fandino D; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas., Anurag M; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.; Department of Medicine, Baylor College of Medicine, Houston, Texas.; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas., Holt MV; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas., Gou X; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas., Pilcher JB; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas., Goetz MP; Department of Oncology, Mayo Clinic, Rochester, Minnesota., Northfelt DW; Division of Hematology and Medical Oncology at Mayo Clinic, Phoenix, Arizona., Hilsenbeck SG; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas., Marshall CG; Repare Therapeutics, Cambridge, Massachusetts., Hyer ML; Repare Therapeutics, Cambridge, Massachusetts., Papp R; Repare Therapeutics, Saint-Laurent, Quebec, Canada., Yin SY; Repare Therapeutics, Saint-Laurent, Quebec, Canada., De Angelis C; Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy., Schiff R; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.; Department of Medicine, Baylor College of Medicine, Houston, Texas.; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas., Fuqua SAW; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas.; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas., Ma CX; Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri., Foulds CE; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.; Department of Medicine, Baylor College of Medicine, Houston, Texas.; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas., Ellis MJ; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas.; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2024 Oct 01; Vol. 23 (10), pp. 1494-1510.

Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus Anastrozole.

Autor: Chapman JW; Canadian Cancer Trials Group Queen's University, Kitchener, Canada., Bayani J; Ontario Institute for Cancer Research, Toronto, Canada.; University of Toronto, Toronto, Canada., SenGupta S; Queen's University, Kingston, Canada., Bartlett JMS; University of Edinburgh, Edinburgh, United Kingdom., Piper T; University of Edinburgh, Edinburgh, United Kingdom., Quintayo MA; Ontario Institute for Cancer Research, Toronto, Canada., Virk S; Canadian Cancer Trials Group Queen's University, Kingston, Canada., Goss PE; Harvard University, Boston, MA., Ingle JN; Harvard University, Boston, MA., Ellis MJ; Progendis, Gaithersburg, MD., Sledge GW; Caris Life Sciences, Irving, TX., Budd GT; Cleveland Clinic, Cleveland, OH., Rabaglio M; Inselspital Bern, Bern, Switzerland., Ansari RH; Indiana School of Medicine, South Bend, IN., Tozer R; McMaster University, Hamilton, Canada., D'Souza DP; London Regional Health Science Centre, London, Canada., Chalchal H; Alan Blair Cancer Center, Regina, Canada., Spadafora S; Algoma Regional Cancer Centre, Sault Ste Marie, Canada., Stearns V; Weill Cornell Medicine, New York, NY., Perez EA; Harvard University, Boston, MA.; Mayo Clinic, Redwood City, CA., Gelmon KA; University of British Columbia, Vancouver, Canada., Whelan TJ; McMaster University, Hamilton, Canada., Elliott C; Canadian Cancer Trials Group Queen's University, Kingston, Canada., Shepherd LE; Canadian Cancer Trials Group Queen's University, Kingston, Canada., Chen BE; Canadian Cancer Trials Group Queen's University, Kingston, Canada., Taylor KJ; University of Edinburgh, Edinburgh, United Kingdom.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Aug 20; Vol. 42 (24), pp. 2887-2898. Date of Electronic Publication: 2024 Jun 02.

Increased Synthetic Cytotoxicity of Combinatorial Chemoradiation Therapy in Homologous Recombination Deficient Tumors.

Autor: Ma J; Departments of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York., Shah R; Departments of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York., Bell AC; Departments of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York., McDermott N; Departments of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York., Pei X; Departments of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York., Selenica P; Pathology, Memorial Sloan Kettering Cancer Center, New York, New York., Haseltine J; Departments of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York., Delsite R; Departments of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York., Khan AJ; Departments of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York., Lok BH; Departments of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York; Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; Departments of Radiation Oncology; Medical Biophysics; Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada., Ellis MJ; Department of Medicine, Baylor College of Medicine, Houston, Texas., Aft RF; Department of General Surgery, Washington University, St Louis, Missouri., Setton J; Departments of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York., Reis-Filho JS; Pathology, Memorial Sloan Kettering Cancer Center, New York, New York., Riaz N; Departments of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: riazn@mskcc.org., Powell SN; Departments of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: powells@mskcc.org.

Publikováno v: International journal of radiation oncology, biology, physics [Int J Radiat Oncol Biol Phys] 2024 Jul 10. Date of Electronic Publication: 2024 Jul 10.

A platform for predicting mechanism of action based on bacterial transcriptional responses identifies an unusual DNA gyrase inhibitor.

Autor: French S; McMaster University, Department of Biochemistry and Biomedical Sciences and Michael G. DeGroote Institute for Infectious Disease Research, Hamilton, ON L8S 4L8, Canada., Guo ABY; McMaster University, Department of Biochemistry and Biomedical Sciences and Michael G. DeGroote Institute for Infectious Disease Research, Hamilton, ON L8S 4L8, Canada., Ellis MJ; McMaster University, Department of Biochemistry and Biomedical Sciences and Michael G. DeGroote Institute for Infectious Disease Research, Hamilton, ON L8S 4L8, Canada., Deisinger JP; McMaster University, Department of Biochemistry and Biomedical Sciences and Michael G. DeGroote Institute for Infectious Disease Research, Hamilton, ON L8S 4L8, Canada., Johnson JW; McMaster University, Department of Biochemistry and Biomedical Sciences and Michael G. DeGroote Institute for Infectious Disease Research, Hamilton, ON L8S 4L8, Canada., Rachwalski K; McMaster University, Department of Biochemistry and Biomedical Sciences and Michael G. DeGroote Institute for Infectious Disease Research, Hamilton, ON L8S 4L8, Canada., Piquette ZA; McMaster University, Department of Biochemistry and Biomedical Sciences and Michael G. DeGroote Institute for Infectious Disease Research, Hamilton, ON L8S 4L8, Canada., Lluka T; McMaster University, Department of Biochemistry and Biomedical Sciences and Michael G. DeGroote Institute for Infectious Disease Research, Hamilton, ON L8S 4L8, Canada., Zary M; McMaster University, Department of Biochemistry and Biomedical Sciences and Michael G. DeGroote Institute for Infectious Disease Research, Hamilton, ON L8S 4L8, Canada., Gamage S; McMaster University, Department of Biochemistry and Biomedical Sciences and Michael G. DeGroote Institute for Infectious Disease Research, Hamilton, ON L8S 4L8, Canada., Magolan J; McMaster University, Department of Biochemistry and Biomedical Sciences and Michael G. DeGroote Institute for Infectious Disease Research, Hamilton, ON L8S 4L8, Canada., Brown ED; McMaster University, Department of Biochemistry and Biomedical Sciences and Michael G. DeGroote Institute for Infectious Disease Research, Hamilton, ON L8S 4L8, Canada. Electronic address: ebrown@mcmaster.ca.

Publikováno v: Cell reports [Cell Rep] 2024 Apr 23; Vol. 43 (4), pp. 114053. Date of Electronic Publication: 2024 Apr 04.